Table 3.

Risk of BCR, second treatment, and PCa mortality, associated with any PSM, PSM site, and multiplicity of sites, derived from competing risk regression models.

Margin statusa	BCRb			Any secondary treatmentc			PCa deathd
	sHR	95% CI	p-Value	sHR	95% CI	p-Value	sHR	95% CI	p-Value
Any PSM vs. negative margin	2.5	2.1–3.1	<0.001	2.9	2.4–3.5	<0.001	1.3	0.8–2.0	0.18
PSM at apex vs. all other casese	1.7	1.3–2.2	<0.001	2.0	1.6–2.5	<0.001	1.3	0.7–2.4	0.39
PSM at bladder neck vs. all other casese	1.9	1.4–2.5	<0.001	1.8	1.3–2.5	<0.001	1.7	0.9–3.5	0.11
PSM at posterolateral vs. all other casese	2.1	1.7–2.5	<0.001	2.3	1.9–2.8	<0.001	0.9	0.6–1.6	0.83
Single PSM site vs. negative	2.3	1.9–2.8	<0.001	2.6	2.1–3.1	<0.001	1.4	0.9–2.2	0.25
Multiple PSM sites vs. negative	3.6	2.6–4.8	<0.001	4.7	3.5–6.3	<0.001	1.2	0.5–2.9	0.66
Intra-prostatic PSM vs. negativef	4.5	3.2–6.3	<0.001	4.8	3.3–7.0	<0.001	0.8	0.3–2.2	0.59

CI, confidence interval; BCR, biochemical recurrence; PCa, prostate cancer; PSM, positive surgical margin; pT, pathological tumor stage.

Note: sHR is the adjusted sub-distribution hazard ratio from competing risk regression models adjusted for age, treatment year, pre-treatment prostate-specific antigen levels, radical prostatectomy Gleason score, and pT.

^aNumber of events per total cases in model (number with competing risk).

^bBCR assessed among men with prostate-specific antigen follow-up recorded, 615 BCR/2640 cases (172 other deaths).

^c551 treated/2818 cases (190 deaths).

^d81 PCa deaths/2818 cases (196 other deaths).

^eMutual adjustment for other margin locations.

^fIntra-prostatic PSMs defined as any PSM in men with pT2 disease, models restricted to pT2 cases.